Subscribe to newsletters

Welcome to Winning The Fight

What is Winning the Fight?

Winning the Fight, Inc., otherwise known as WFND, is a 100% volunteer, 501(c)3 non-profit organization with a home base in Tampa, FL, and a network of volunteers and donors around the world. We are dedicated to raising awareness about neurodegenerative diseases (NDs), as well as seeking and funding new treatments for NDs.


We strive to slow the progression of these diseases to extend the lives of those affected and enhance quality of life until a cure is found. We raise funds by hosting events, internet campaigning, and also by submitting grant proposals to a variety of prospective corporate and non-profit donors.


 Winning the Fight consists of a board of directors, a medical liaison, and a sizable network of loyal volunteers to run the organization and raise money nationwide, in Europe, and Canada. We also rely on a team of scientists to conduct research. Within our volunteer network, there are specialists in neuroscience, finance, business, and information technologies, along with attorneys and physicians. These individuals graciously donate their time, services, and expertise to help WFND expand and improve. Due to the fact that WFND is comprised entirely of volunteers, we are able to dedicate all net proceeds to our mission to discover and to test treatments for people with NDs, and to promote ND awareness. It is imperative that we focus on stopping or decelerating the progression of these diseases to allow affected individuals to survive longer and also achieve a better quality of life until a cure is found. We have already discovered an ND  treatment   that has been successful in several patients and we are currently conducting laboratory studies to confirm our testimonial evidence. 

 Winning the Fight’s  volunteers   maintain relationships with other non-profits focused on neurodegenerative diseases by providing volunteer services and participating in fundraising and awareness events hosted by these organizations. Our volunteers currently maintain relationships with the ALS Association and the Johns Hopkins Robert Packard Center for ALS Research. We aim to continue networking and offering our services within the non-profit community, and to develop relationships with organizations focused on fighting both ALS and other neurodegenerative diseases.


What are neurodegenerative diseases?

Neurodegenerative diseases (NDs) are a group of diseases that cause the progressive and irreversible death of nerve cells and muscle cells. Examples of NDs include Alzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Parkinson’s Disease (PD), but there are many more. These four NDs alone plague approximately 7 million Americans and approximately 50 million worldwide. Neurodegenerative diseases affect men and women of all ages, ethnicities, and income levels. Patients gradually become paralyzed due to the lost ability to control their muscles, and most eventually die from complications related to the paralysis. The most aggressive NDs can kill a patient less than 2 years after onset, while the least aggressive NDs usually leave patients severely handicapped for life. Many believe that, in all NDs, cell death occurs due to lack of energy delivered to the cells. NDs also have in common the accumulation of glutamate in the body, which causes muscle twitching and lack of muscular control.



ALS Untangled wrote an article evaluating the Deanna Protocol - Sunday, August 4, 2013
ALS Untangled wrote an article evaluating the Deanna Protocol and addressed several concerns. WFND has responded and answered ALS Untangled's concerns in a separate article. Please see ALS Untangled's article and WFND's responding article.
FDA Hearing Highlights ALS Drug Development Concerns - Wednesday, February 27, 2013
•At a public hearing Monday, Feb. 25, 2013, conducted by the U.S. Food and Drug Administration, people with ALS and their families, clinicians and other medical professionals urged the FDA to consider the unique needs of patients and their families — for whom time is of the essence — when considering trial design and review of therapies for ALS. •Input in the form of verbal and written remarks was given by patients, caregivers, advocates, health care providers, academia, industry and others — including MDA President and CEO Steven M. Derks and Stan Appel, who directs the MDA/ALS Center at Methodist Neurological Institute in Houston. •The public may continue to submit comments to the FDA on this subject through March 25, 2013.
Taking on the Fight Against Lou Gehrig's Disease - Monday, February 25, 2013
Deanna Tedone-Gage sits down with Tampa Tribune reporter Jessica Balanza and talks about her valiant fight against Lou Gehrig's Disease.